Thyroid cell growth and function are regulated by hormones and growth factors binding to cell surface receptors that are coupled via G proteins, Gs and Gq, to the adenylyl cyclase and phospholipase C signal transduction systems, respectively. Activating mutations of the TSH receptor and G␣s have been documented in subsets of thyroid neoplasms. To test the oncogenic potential of activated G␣s in transgenic mice, we used the cholera toxin A1 subunit that constitutively activates G␣s and used the rat thyroglobulin gene promoter for targeting this transgene (TGCT) to thyroid follicular cells. Three (M1392, F1358, and F1286) of six founders identified were able to transmit the transgene to their offspring and thyroid glands from these mice contained elevated levels of cAMP. Concentrations of serum thyroxine were elevated as early as 2 months of age (M 1392 and F 1286). F1358 mice were euthyroid until 8 months of age, at which time they developed hyperthyroidism. All three TGCT lines developed thyroid hyperplasia independent of their thyroxine levels. DNA image analysis of thyroid follicular cells from both the hyper and euthyroid mice showed that DNA index and "SϩG2/M" phase were increased compared with normal, changes similar to that seen in poor prognosis human carcinomas. These data suggest that the G␣s-adenylyl cyclase-cAMP pathway has an important role in thyroid hyperplasia and the transgenic mouse models reported herein will allow further examination of the role of this pathway in thyroid oncogenesis. (Endocrinology 138: [3133][3134][3135][3136][3137][3138][3139][3140] 1997) T HYROID FOLLICULAR cell growth and function is primarily controlled by TSH. Binding of TSH to its receptor leads to activation, via G proteins (G␣s and G␣/G␣ 11 ) of the adenylyl cyclase (AC) and phospholipase C (PLC) signaling pathways, respectively (1-3). Several studies suggest that TSH is involved not only in normal physiological growth but also in thyroid tumorigenesis (4, 5). Indirect evidence implicating TSH in the development of thyroid neoplasia includes work by Jemec in 1980 that showed thyroid hormone administration and hypophysectomy prevented thyroid hyperplasia and neoplasia in rats given the goitrogen, 1-methyl-2-mercapto-imidazol (MMI) (6). Clinical evidence includes: 1) the observation that there is an increased incidence of follicular and anaplastic carcinoma in areas with concomitant endemic goiters (7, 8); and 2) that suppression of TSH by administration of thyroid hormone decreases the local recurrence rate as well as the rate of distant metastases in patients with thyroid cancer (9, 10). Relevant to our study, activating mutations in both G␣s and the TSH receptor, which increase cAMP, have been documented in hyperfunctioning adenomas and differentiated thyroid carcinomas (11-16), further supporting the involvement of the TSH-G␣s-AC-cAMP pathway in thyroid oncogenesis.
T HYROID FOLLICULAR cell growth and function is primarily controlled by TSH. Binding of TSH to its receptor leads to activation, via G proteins (G␣s and G␣/G␣ 11 ) of the adenylyl cyclase (AC) and phospholipase C (PLC) signaling pathways, respectively (1) (2) (3) . Several studies suggest that TSH is involved not only in normal physiological growth but also in thyroid tumorigenesis (4, 5) . Indirect evidence implicating TSH in the development of thyroid neoplasia includes work by Jemec in 1980 that showed thyroid hormone administration and hypophysectomy prevented thyroid hyperplasia and neoplasia in rats given the goitrogen, 1-methyl-2-mercapto-imidazol (MMI) (6) . Clinical evidence includes: 1) the observation that there is an increased incidence of follicular and anaplastic carcinoma in areas with concomitant endemic goiters (7, 8) ; and 2) that suppression of TSH by administration of thyroid hormone decreases the local recurrence rate as well as the rate of distant metastases in patients with thyroid cancer (9, 10) . Relevant to our study, activating mutations in both G␣s and the TSH receptor, which increase cAMP, have been documented in hyperfunctioning adenomas and differentiated thyroid carcinomas (11) (12) (13) (14) (15) (16) , further supporting the involvement of the TSH-G␣s-AC-cAMP pathway in thyroid oncogenesis.
Two transgenic mouse models that examine the oncogenic potential of constitutively elevated cAMP in the thyroid have been developed; one in which G␣s with an activating mutation (G␣s R201H ) is expressed (17) , and one in which the A2 adenosine receptor is overexpressed (18) . Transgenic mice expressing G␣s R201H develop hyperfunctioning thyroid adenomas that are associated with elevated cAMP levels, increased radioactive iodine uptake, as well as elevated serum triiodothyronine and thyroxine levels. Transgenic mice overexpressing the A2 adenosine receptor develop thyroid hyperplasia and hyperthyroidism in association with a constitutively activated cAMP cascade (18) .
Because the G␣s R201H mouse model still expresses endogenous, nonactivated G␣s, and because signaling pathways activated by the A2 adenosine receptor may exist that heretofore have not been described, we chose to create a transgenic mouse model in which, theoretically, G␣s molecules are more specifically and more completely activated. To accomplish this, we used the cholera toxin A1 subunit (CT) and placed it under the control of the thyroid-specific thyroglobulin gene promoter (TG). Three transgenic mouse lines were created that developed thyroid hyperplasia. Mice from two of these lines were hyperthyroid as early as two month of age, and mice from the third line were euthyroid until 8 months of age, at which time they become hyperthyroid. The DNA index and proliferation fraction were elevated in all three lines and aneuploidy, measured by DNA cytometry, was similar to that seen in poor prognosis human carcinomas (19 -22) . We believe that our results both confirm and expand upon previous studies that implicate the G␣s-AC-cAMP pathway in thyroid neoplasia (17, 18) .
Materials and Methods

Materials and mice
Restriction enzymes were from New England Biolabs, Inc. (Beverly, MA). Taq polymerase and PCR-related products were purchased from Perkin Elmer Co. (Norwalk, CT). B6/C3 and FVB/N mice were from Charles River Laboratory (Wilmington, MA). Unless otherwise indicated, all other reagents were obtained from Sigma Chemical Co. (St. Louis, MO).
The animal protocols (MO93M028 and MO96M164) have been approved by the Animal Care and Use Committee at Johns Hopkins University.
Transgenic mice, Southern analysis and PCR
We have previously detailed the creation of a functional pUC plasmid containing the thyroglobulin gene promoter (TG), the cholera toxin A1 subunit (CT), and polyadenylation signal sequence derived from the human GH (hGH) gene (23) (24) (25) (26) . Although the 3Ј-untranslated region contains the entire hGH and polyadenylation signal sequence, hGH is not expressed, because there is no promoter region for the hGH in this transgene. In addition, hGH was not detected in the conditioned medium of FRTL-5 cells transfected with this construct (24 -26) nor in cell suspensions from thyroid glands of the transgenic mice (data not shown). The TGCT transgene was excised from pUC by digestion with KpnI and EcoRI enzymes ( Fig. 1) and microinjected into the pronucleus of single cell B6/C3 F1 mouse embryos at the Johns Hopkins University Transgenic Core Facility (27) . The injected cells were then implanted into the oviduct of CD-1 pseudo-pregnant mice. Identification of transgenic founder mice was done by PCR and Southern analysis of genomic DNA that was extracted from tail biopsies of 3-week-old pups (28) . Fivemillimeter tail biopsies were taken from each mouse, and DNA was extracted overnight at 37 C in the following buffer: 1% SDS, 50 mm Tris-HCl, pH 8, 20 mm NaCl, 1 mm EDTA, and proteinase K (final concentration 1 mg/ml; Life Technologies, Gaithersburg, MD). The quality of tail DNA was assessed by testing the ability to amplify the gene for mouse milk protein (MWAP) (28) . One microliter of a 1/10 dilution of this crude DNA solution was used for PCR amplification of the TGCT minigene using the following protocol: 1 l template was mixed with 20 pmol of each primer, 200 m each dNTP, 10 mm Tris-HCl, 1.5 mm MgCl 2 , 50 mm KCl, and 2.5 U Taq DNA polymerase in a volume of 100 l, and was amplified for 35 cycles consisting of denaturation at 94 C for 1 min, annealing at 54 C for 1 min, and extension at 72 C for 2 min. Final extension was continued for 7 min. The PCR products were then electrophoresed on a 2% agarose gel in Tris-Borate-EDTA buffer [100 mm Tris-HCl, pH 8.3, 100 mm boric acid, and 2 mm EDTA (Biofluids, Inc., Rockville, MD)] and stained with ethidium bromide. HaeIII-digested x174 RF DNA (New England Biolabs) was used to determine size of PCR products. For Southern blot analysis, genomic DNA was extracted from the crude DNA preparations of mouse tail by phenol/ FIG. 1. The cholera toxin A1 subunit gene (CT, 0.6 kb) and 3Ј-untranslated region (2.1 kb), which includes hGH, its polyadenylation signal, and intron, were used. The thyroglobulin gene promoter (TG, 0.8 kb) replaced the hGH promoter. For PCR screening, primers were designed to amplify the region overlapping the TG promoter and CT; the size of its PCR product was 436 bp. For Southern blot analysis, radiolabeled 3Ј-untranslated region was used as a probe. chloroform extraction and precipitated with isopropanol. 10 g DNA in TE buffer (10 mm Tris-HCl, pH 7.5, and 0.1 mm EDTA) was digested with DNA endonuclease, including BamHI and EcoRI (New England Biolabs), size-fractionated on a 0.8% agarose gel containing 1 g/ml ethidium bromide, transferred to nylon membranes (Schleicher & Schuell, Keene, NH) and probed with the [ 32 P]-labeled 3Ј-untranslated region of the TGCT gene (Fig. 1) . HindIII-digested page DNA (New England Biolabs) was used to determine size of digested genomic DNA.
FIG. 2. PCR amplification of the TGCT gene from transgenic (lanes
T 4 and TSH levels in blood
Blood samples were obtained by subxiphoid cardiac puncture of mice that were under pentobarbital-induced anesthesia, or from tail veins, and spotted onto filter paper (gel blot paper GB002, Schleicher & Schuell). Blood T 4 levels were then measured by Neonatal T 4 125 I RIA kit (ICN Pharmaceuticals, Inc., Costa Mesa, CA). Serum was collected after centrifugation of blood at 3000 rpm for 10 min. Although a mousespecific TSH immunoassay is not available, antirat TSH antibody crossreacts with mouse TSH (29) . We therefore measured mouse TSH levels using a rat TSH RIA kit provided by the National Institute of Diabetes, Digestive, and Kidney Diseases, National Institutes of Health [NIDDKrTSH-I-9 (AFP-11542B), NIDDK-antirat TSH-RIA-6 (AFP329691Rb), NIDDK-rTSH-RP-3 (AFP-5512B), and mouse TSH (AFP51718MP)] as described previously (29) .
cAMP production
Thyroid glands were removed from mice euthanized with 5-10 mg pentobarbital (Abbott Laboratories, North Chicago, IL). Each thyroid gland was incubated at 37 C for 1 h in 300 l NaCl-free HBSS containing 0.4% BSA and 0.5 mm isobutyl-methylxanthine (25) . After the addition of 1 ml 5% perchloric acid, samples were homogenized and centrifuged to remove protein debris (1, 25) . Supernatants were recovered and neutralized with 5 m KOH and recentrifuged to remove insoluble salts. Total cAMP from one aliquot of the supernatant was measured by RIA (DuPont-New England Nuclear, Boston, MA) (1, 25) . Diphenylamine solution was added to the pellets to measure DNA (25, 30) . Values are reported as pmol cAMP/g DNA.
Histology
Thyroids glands were fixed in 10% formalin and embedded in paraffin. Five-micrometer sections were stained with hematoxylin-eosin stain and slides were reviewed by a single pathologist (WHW) in a blinded fashion.
Image cytometry
Five-micrometer sections from formalin-fixed and paraffin-embedded tissue were deparaffinized. Touch preparations from fresh thyroid tissues were also used. They were Feulgen-stained (Becton Dickinson, Elmhurst, IL) by hydrolysis in 4 n HCl at 28 C for 1 h. Sections were then incubated in CAS DNA staining reagent (Becton Dickinson) for 1 h at room temperature in the dark, rinsed in 0.25% sulfite water and 0.5 n HCl three times for 5 min each, air dried for 3 h, and mounted with Accu Mount 60 (Baxter Healthcare Co., McGaw Park, IL) (31).
Feulgen-stained thyroid cells were analyzed using the computerized CAS 200 Image Cytometer (Becton Dickinson) with a 40ϫ achromatic lens. 500 nuclei per slide were measured. Data were collected on total DNA, DNA index, nuclear size, nuclear shape and 20 separate Marcovian-Nuclear texture features. DNA histograms were analyzed with the CAS Cell Measurement program version 3.0 (Becton Dickinson). Ploidy value was determined as the major peak value of DNA Index histogram. The fraction of cells in S-phase and G2/M phases of cell cycle was estimated by standard modeling software.
Statistical analysis
All assays were performed in duplicate. Differences between groups were evaluated by ANOVA. The statistical significance of the differences was determined by Student's t test or Cochran-Cox's test, when the variation in the data were uniform or not uniform, respectively. Values were considered significant at P Ͻ 0.05.
Results
Transgenic mice
Six founders carrying the TGCT transgene were identified by PCR (Fig. 2) and Southern blot analysis (Fig. 3) of DNA from offspring. Two founder mice (M1363 and F1394) were infertile and died at 1 and 5 months, respectively. M1382 was unable to transmit transgene DNA. Only three (M1392, F1286, and F1358) of the six founders survived, were able to transmit the transgene to their offspring, and form the basis of this report. Southern blot analysis showed that these three founders carried between 1 and 3 copies of the transgene (Fig. 3) . Because the B6/C3 mouse strain exhibit spontaneous thyroid abnormalities, including thyroid neoplasia in 2.3% of mice between 90 and 110 weeks of age (32), we cross-bred the TGCT founders with FVB/N mice (33), a strain that exhibits no thyroid abnormalities (34) .
Thyroid function
Blood thyroxine levels were significantly elevated as early as 2 months of age in mice from the M1392 (19.6 Ϯ 5.2 g/dl, n ϭ 14) and F1286 (17.5 Ϯ 4.3 g/dl, n ϭ 4) lines compared with normal (6.1 Ϯ 1.8 g/dl, n ϭ 14) (Fig. 4) . Serum levels of TSH were undetectable in these hyperthyroxinemic mice, confirming hyperthyroidism (data not shown). Mouse TSH from control mice between 2 and 4 months of age was 17.8 Ϯ 8.9 ng/ml (n ϭ 14). Mice from the transgenic line F1358 were euthyroid (T 4 , 6.0 Ϯ 1.9 g/dl, n ϭ 15) for 4 months (Fig. 4) , but some of the mice developed hyperthyroxinemia after 8 months. The average thyroxine levels were significantly lower in younger mice (Յ8 months, 6.4 Ϯ 1.9 g/dl, n ϭ 17) than in older mice (Ն8 months, 10.0 Ϯ 4.7 g/dl, n ϭ 13) (Fig.  5) . Half the offspring from the hyperthyroid lines (M1392 and F1286) were treated empirically with 0.05% methimazole (MMI) and 5 g/ml thyroxine in their drinking water. Females from of these lines were infertile unless treated with MMI and thyroxine.
Most transgenic mice from the M1392 and F1286 lines that were untreated with MMI and thyroxine, as well as the founders M1363 and F1394, died within 3-5 months, presumably from hyperthyroidism. The exact reason of death in these mice, however, was not determined and necropsy revealed thyromegaly and thyroid hyperplasia, but without evidence of cardiac hypertrophy. Untreated mice from these lines also exhibited growth retardation compared with their control littermates (50 -80% of control's weight). Furthermore, treated mice with MMI and thyroxine lived longer than untreated mice by 8 months.
cAMP levels
Thyroids from M1392, F1286, and F1358 mice that had not been treated with MMI and thyroxine were examined. Basal levels of cAMP were significantly elevated in all three lines: M1392 (1.65 Ϯ 0.59 pmol/g DNA, n ϭ 3), F1286 (1.05 Ϯ 0.82 pmol/g DNA, n ϭ 3), and F1358 (0.96 Ϯ 0.92 pmol/g DNA, n ϭ 8) compared with control (0.08 Ϯ 0.03 pmol/g DNA, n ϭ 6) (Fig. 6) . cAMP levels in thyroids from M1392 and F1286 mice were elevated as early as 2 months of age. In contrast, cAMP levels in thyroids from the euthyroid F1358 mice increased in an age-dependent manner after 3 months (Fig. 7) . There was no correlation between cAMP and T 4 levels (data not shown).
Histology
Ten of 10 thyroids from line M1392, 2 of 2 from F1286, and 14 of 18 from F1358 exhibited thyromegaly grossly (Fig. 8 ) and hyperplasia histologically (Fig. 9) . More severe thyroid hyperplasia was seen in the hyperthyroid M1392 and F1286 lines than in the euthyroid F1358 line at the same age (2-4 months of age). One striking feature seen microscopically was the papillary pattern associated with intense mitotic activity, despite the absence of infiltration, psammoma bod- ies or the cytological features that are associated with papillary cancer (Fig. 9) .
Thyroid glands from mice that had been treated with MMI and thyroxine were also examined at 8 months of age. They exhibited thyromegaly and hyperplasia. Although more severe hyperplasia was seen in the MMI-treated mice, there was still no evidence of solitary nodule formation or invasion.
DNA image cytometry
Three thyroids from each of the M1392 and F1358 lines were examined by DNA image cytometry. All exhibited both an increase in their DNA index and "S ϩ G2/M" phase (Table 1) , consistent with the development of aneuploidy and an increase in mitosis. The most dramatic changes were seen 5ϫ and c, 25ϫ) . In addition to enlarged follicles, papillary growth is seen in transgenic mouse thyroids (c). Higher magnification (100ϫ) of control mouse thyroid (d) and transgenic mouse thyroid (e).
in one animal (M143) from line M1392 whose thyroid had three aneuploid peaks (Fig. 10) . These changes in DNA cytometry were similar to that seen in poor prognosis human carcinomas (19 -22) .
Discussion
Somatic cell mutations of both oncogenes and tumor suppressor genes (eg, ras, gsp, ret, p53) have been documented in both papillary and follicular thyroid neoplasms and have been proposed by others to be responsible for the initiation and progression of thyroid tumors (35, 36) . Goretzki et al. (14) have documented mutations of ras and G␣s (gsp) in up to 69% of well differentiated thyroid carcinomas. Similarly, Zou et al. have demonstrated p53 mutations in both well differentiated and anaplastic thyroid carcinomas (37) . There also exists clinical and pathological evidence that well differentiated carcinomas may progress to anaplastic carcinomas (38, 39) . Two studies (39, 40) have demonstrated the presence of well differentiated thyroid carcinoma in up to 50% of anaplastic carcinomas on pathological sections. Additional supporting evidence that thyroid tumors may arise via a series of mutational events includes the fact that these tumors are of monoclonal origin (41) (42) (43) and therefore likely result from multiple and complimentary mutational events (44) , although the possibility that a single hit may cause thyroid neoplasm, cannot be excluded (45) .
Activating mutations of the TSH receptor and G␣s lead to elevated cAMP levels and have been postulated to represent early events associated with the development of thyroid neoplasia. In this study, we created transgenic mice in which CT expression results in elevated cAMP, hyperthyroxinemia, thyromegaly and thyroid hyperplasia. Although there was no direct evidence by Northern analysis or Western blotting that the CT was expressed, the data from PCR and Southern analysis suggest correct integration of CT, and the documented cAMP elevation indicates that the CT gene was indeed translated.
In addition to the current study, two previous transgenic models that examined the G␣s-AC-cAMP pathway (17, 18) lend credence to the proposed hypothesis. In contrast to transgenic mice expressing an activated form of G␣s (G␣s R201H ) that develop nodular thyroid hyperplasia (17), TGCT mouse lines develop diffuse hyperplasia and at an earlier age (2 months vs. 8 months, respectively). Different promoters (bovine TG in the G␣s model vs. rat TG in the TGCT model) may account for this finding. The difference between these two phenotypes may also be a result of the number of activated G␣s molecules or the extent to which it is activated: the TGCT transgene activates all endogenous G␣s protein in thyroid cells (26) , whereas in G␣s R201H transgenic mice, only a subset of G␣s are activated. Although the complete activation of G␣s may not be required to develop thyroid neoplasia, comparison of the degree of activation may still be relevant. Likewise, the A2 adenosine receptor transgenic model is associated with elevated cAMP levels (18) , but the A2 adenosine receptor pathway may be associated with activation of other signal transduction pathways heretofore not described. In our model, there was no concomitant stimulation of the PLC pathway (data not shown). In this respect, our model may therefore provide a more complete and more specific activation of G␣s than the previous models.
The basis for the different phenotypes exhibited by the 3 TGCT lines remains unclear but may be explained by the different cAMP levels. Thyroid glands from two lines (M1392 and F1286) showed high levels of basal cAMP and hyperthyroidism as early as two month of age. In contrast, mice from F1358 were euthyroid until 8 months of age with correspondingly lower cAMP levels. The cAMP levels in F1358 Two thyroids from control mice and three thyroids from each of two lines (M1392 and F1358) were examined by DNA image cytometry. Ploidy value was determined as the major peak value of DNA Index histogram and expressed as % of control. The percentage of "S ϩ G2/M" phase was determined from the DNA Index histogram. All thyroids from TGCT transgenic mice showed an increase in DNA index and "S ϩ G2/M" phase in comparison to control thyroid glands. Thyroids from M143 and M784 showed three and two peak values of DNA index, respectively ( a ). thyroids increased after 3 months and the mice developed hyperthyroidism after 8 months. Although there was no correlation between cAMP levels in the thyroid glands and blood thyroxine level in F1358, cAMP level itself may explain the variations in phenotype. Although cAMP elevation can mimic TSH-induced iodide uptake in vivo (46, 47) , its elevation may require a longer time to cause hyperthyroidism. In addition, activated G␣s mutations are reported in nonfunctioning as well as functioning thyroid tumors (11) (12) (13) (14) , suggesting that elevated levels of cAMP may not always be associated with increased hormone synthesis. Further examination of protein kinase A and other distal components of the cAMP pathway in younger euthyroid F1358 mice may provide insight into this phenomenon.
We have previously reported that FRTL-5 cells permanently transfected with the TGCT transgene have markedly elevated levels of cAMP and undergo malignant transformation when implanted into nude mice (26) . The transgenic mice in this study developed thyroid hyperplasia but showed no evidence of neoplasia. This discrepancy may reflect a difference in host immune cell recognition phenomena with rat thyroid follicular cells transfected with the TGCT minigene able to undergo unchecked malignant transformation in nude mice. Alternatively, although FRTL-5 cells maintain normal thyroid cell characteristics, including TSHdependent growth and iodide uptake (48, 49) , it is reasonable to presume that these immortalized cells already harbor another mutation(s), such that with the introduction of TGCT, the cells experienced an additional hit that confers a malignant phenotype (44) . In support of this concept, a recent clinical report suggests (50) that elevation of cAMP alone may be insufficient to induce thyroid neoplasia. Our data confirm this hypothesis.
Both the histology and the DNA cytometry present in thyroid glands from our TGCT model are, however, consistent with early steps seen in thyroid neoplasia. This is supported by the fact that the aneuploidy peaks demonstrated in some of the TGCT thyroid glands are seen only in poorly differentiated human carcinomas (19 -22) . There were no definitive features of papillary carcinoma seen in our model and yet, intense mitotic activity was observed, a feature associated with thyroid neoplasia and not hyperplasia (19 -22) . With MMI and thyroxine treatment to prevent premature death from hyperthyroidism, thyroid malignancy may still develop over time in these transgenic lines.
In summary, we have both confirmed and extended the hypothesis that G␣s-AC-cAMP pathway is involved in thyroid hyperplasia. Although our TGCT model of thyroid hyperplasia and hyperthyroxinemia suggests that stimulation of the cAMP signaling pathway is insufficient to promote malignant thyroid growth in mice, further studies are still needed to fully understand the underlying mechanism of thyroid oncogenesis.
